Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

For important updates on recent policy changes, please click here for more details.

Merck
CN

IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function.

Cancer immunology research (2020-01-23)
Michael St Paul, Samuel D Saibil, Scott C Lien, SeongJun Han, Azin Sayad, David T Mulder, Carlos R Garcia-Batres, Alisha R Elford, Kavita Israni-Winger, Céline Robert-Tissot, Michael Zon, Sarah Rachel Katz, Patricia A Shaw, Blaise A Clarke, Marcus Q Bernardini, Linh T Nguyen, Benjamin Haibe-Kains, Trevor J Pugh, Pamela S Ohashi
ABSTRACT

CD8+ T cells can be polarized into several different subsets as defined by the cytokines they produce and the transcription factors that govern their differentiation. Here, we identified the polarizing conditions to induce an IL22-producing CD8+ Tc22 subset, which is dependent on IL6 and the aryl hydrocarbon receptor transcription factor. Further characterization showed that this subset was highly cytolytic and expressed a distinct cytokine profile and transcriptome relative to other subsets. In addition, polarized Tc22 were able to control tumor growth as well as, if not better than, the traditional IFNγ-producing Tc1 subset. Tc22s were also found to infiltrate the tumors of human patients with ovarian cancer, comprising up to approximately 30% of expanded CD8+ tumor-infiltrating lymphocytes (TIL). Importantly, IL22 production in these CD8+ TILs correlated with improved recurrence-free survival. Given the antitumor properties of Tc22 cells, it may be prudent to polarize T cells to the Tc22 lineage when using chimeric antigen receptor (CAR)-T or T-cell receptor (TCR) transduction-based immunotherapies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
ADP/ATP Ratio Assay Kit, sufficient for 100 tests (bioluminescent)
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
0.5 mL
Available to ship on April 18, 2025
Details...
CN¥1,600.33
1 mL
Available to ship on April 18, 2025
Details...
CN¥2,506.37
2 mL
Available to ship on April 18, 2025
Details...
CN¥4,025.34